Literature DB >> 32370571

The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.

Sarita Shrestha1, Ola Olén2,3,4, Carl Eriksson3,5, Åsa H Everhov2,3, Pär Myrelid6,7, Isabella Visuri5, Jonas F Ludvigsson8,9,10,11, Ida Schoultz1, Scott Montgomery3,12,13, Michael C Sachs3, Jonas Halfvarson5, Malin Olsson14, Henrik Hjortswang15, Jonas Bengtsson16, Hans Strid17, Marie Andersson17, Susanna Jäghult18, Michael Eberhardson19, Caroline Nordenvall20,21, Jan Björk22,23, Ulrika L Fagerberg24,25,26, Martin Rejler27,28, Olof Grip29, Pontus Karling30, Mattias Block31, Eva Angenete32,33, Per M Hellström29, Anders Gustavsson34,35.   

Abstract

Introduction: Whether data on International Classification of Diseases (ICD)-codes from the Swedish National Patient Register (NPR) correctly correspond to subtypes of inflammatory bowel disease (IBD) and phenotypes of the Montreal classification scheme among patients with prevalent disease is unknown.Materials and methods: We obtained information on IBD subtypes and phenotypes from the medical records of 1403 patients with known IBD who underwent biological treatment at ten Swedish hospitals and retrieved information on their IBD-associated diagnostic codes from the NPR. We used previously described algorithms to define IBD subtypes and phenotypes. Finally, we compared these register-generated subtypes and phenotypes with the corresponding information from the medical records and calculated positive predictive values (PPV) with 95% confidence intervals.
Results: Among patients with clinically confirmed disease and diagnostic listings of IBD in the NPR (N = 1401), the PPV was 97 (96-99)% for Crohn's disease, 98 (97-100)% for ulcerative colitis, and 8 (4-11)% for IBD-unclassified. The overall accuracy for age at diagnosis was 95% (when defined as A1, A2, or A3). Examining the validity of codes representing disease phenotype, the PPV was 36 (32-40)% for colonic Crohn's disease (L2), 61 (56-65)% for non-stricturing/non-penetrating Crohn's disease behaviour (B1) and 83 (78-87)% for perianal disease. Correspondingly, the PPV was 80 (71-89)% for proctitis (E1)/left-sided colitis (E2) in ulcerative colitis.Conclusions: Among people with known IBD, the NPR is a reliable source of data to classify most subtypes of prevalent IBD, even though misclassification commonly occurred in Crohn's disease location and behaviour and also among IBD-unclassified patients.

Entities:  

Keywords:  Crohn’s disease; ICD-codes; Inflammatory bowel disease; Montreal classification; National Patient Register; Swedish Quality Register for IBD; epidemiology; ulcerative colitis; validation

Mesh:

Year:  2020        PMID: 32370571     DOI: 10.1080/00365521.2020.1740778

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.

Authors:  Jordan E Axelrad; Michael C Sachs; Jonas F Ludvigsson; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-10-09       Impact factor: 4.790

2.  No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.

Authors:  Dominic Picetti; Jihoon Kim; Wenhong Zhu; William J Sandborn; Vipul Jairath; Siddharth Singh
Journal:  Dig Dis Sci       Date:  2021-11-19       Impact factor: 3.487

3.  Comprehensive National Inpatient Sample data reveals low but rising Pneumocystis jiroveci pneumonia risk in inflammatory bowel disease patients.

Authors:  Jeffrey Schwartz; Daniel J Stein; Joseph D Feuerstein
Journal:  Ann Gastroenterol       Date:  2022-04-08

4.  Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.

Authors:  Sara Rundquist; Michael C Sachs; Carl Eriksson; Ola Olén; Scott Montgomery; Jonas Halfvarson
Journal:  Aliment Pharmacol Ther       Date:  2020-12-19       Impact factor: 8.171

5.  Identification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study.

Authors:  Natalia Mouratidou; Petter Malmborg; Jacob Järås; Vignir Sigurdsson; Olof Sandström; Ulrika L Fagerberg; Gabriella Bröms; Jonas F Ludvigsson; Ola Olén
Journal:  Clin Epidemiol       Date:  2022-04-29       Impact factor: 5.814

6.  Probability of Stoma in Incident Patients With Crohn's Disease in Sweden 2003-2019: A Population-based Study.

Authors:  Åsa H Everhov; Thordis Disa Kalman; Jonas Söderling; Caroline Nordenvall; Jonas Halfvarson; Anders Ekbom; Jonas F Ludvigsson; Ola Olén; Pär Myrelid
Journal:  Inflamm Bowel Dis       Date:  2022-08-01       Impact factor: 7.290

7.  Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates.

Authors:  Michael Eberhardson; Pär Myrelid; Jonas K Söderling; Anders Ekbom; Åsa H Everhov; Charlotte R H Hedin; Martin Neovius; Jonas F Ludvigsson; Ola Olén
Journal:  Colorectal Dis       Date:  2022-01-22       Impact factor: 3.917

8.  Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register.

Authors:  Joel Thunberg; Olle Björkqvist; Charlotte R H Hedin; Anders Forss; Charlotte Söderman; Daniel Bergemalm; Ola Olén; Henrik Hjortswang; Hans Strid; Jonas F Ludvigsson; Carl Eriksson; Jonas Halfvarson
Journal:  United European Gastroenterol J       Date:  2022-07-14       Impact factor: 6.866

9.  Associations between inflammatory bowel disease, social isolation, and mortality: evidence from a longitudinal cohort study.

Authors:  Jie Chen; Jiawei Geng; Jiayi Wang; Zhenhua Wu; Tian Fu; Yuhao Sun; Xuejie Chen; Xiaoyan Wang; Therese Hesketh
Journal:  Therap Adv Gastroenterol       Date:  2022-09-30       Impact factor: 4.802

10.  Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data.

Authors:  Karoline Freeman; Sian Taylor-Phillips; Brian H Willis; Ronan Ryan; Aileen Clarke
Journal:  BMJ Open       Date:  2021-02-22       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.